Mirum's Livmarli Receives FDA Approval for Treating Cholestatic Pruritus

Thursday, 14 March 2024, 10:35

Mirum Pharmaceuticals' Livmarli has gained FDA acceptance for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic. The FDA approval of the label expansion of this liver disease drug marks a significant milestone for Mirum and provides new treatment options for a specific category of patients suffering from this condition. The approval showcases the effectiveness and potential positive impact of Livmarli in addressing the unmet needs of patients with cholestatic pruritus.

https://store.livarava.com/0dc60e4c-e1f0-11ee-966f-5254a2021b2b.jpe — Mirum's Livmarli Receives FDA Approval for Treating Cholestatic Pruritus

Mirum's Livmarli Receives FDA Approval

Mirum Pharmaceuticals' Livmarli has gained FDA acceptance for the treatment of cholestatic pruritus in patients with progressive familial intrahepatic.

Significant Milestone for Mirum

The FDA approval of the label expansion of this liver disease drug marks a significant milestone for Mirum and provides new treatment options for a specific category of patients suffering from this condition.

Effectiveness of Livmarli

The approval showcases the effectiveness and potential positive impact of Livmarli in addressing the unmet needs of patients with cholestatic pruritus.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.